The rate of KRAS mutations was 92% (24/26), TP53 mutations was 50% (13/26), CDKN2A mutations was 15% (4/26), and SMAD4 mutations was 31% (8/26) on cancer gene panel testing (Fig 2 and Table 1). Here, CDKN2A is linked to cancer.